

effects of IFN $\beta$ -1a on all biological levels including pharmacodynamics, MRI activity, and clinical response.<sup>2</sup> The rate of NAb positivity in patients treated with this particular preparation of IFN $\beta$ -1a is approximately 20% and persistency of NAb over many years is very likely.<sup>3,4</sup> Even in patients with transient NAb, disease activity is higher during NAb-positive than NAb-negative periods.<sup>2</sup> Moreover, a study of such a long duration would have been ideally suited for NAb analysis because the clinical consequences of NAb occur only after 2 years on medication.<sup>2</sup> To recognize the “true” superiority of alemtuzumab over IFN $\beta$ -1a, the subgroup of persistently NAb-negative patients on the latter treatment arm should have been analyzed separately. In a world where biomarkers have become of central interest in MS research and guidelines include NAb in treatment decisions,<sup>5</sup> it is surpris-

ing that such a reliable biomarker of treatment response can still be ignored.

Copyright © 2012 by AAN Enterprises, Inc.

1. Coles AJ, Fox E, Vladoic A, et al. Alemtuzumab more effective than interferon  $\beta$ -1a at 5-year follow-up of CAMMS223 Clinical Trial. *Neurology* 2012;78:1069–1078.
2. Deisenhammer F. Neutralizing antibodies to interferon-beta and other immunological treatments for multiple sclerosis: prevalence and impact on outcomes. *CNS Drugs* 2009;23:379–396.
3. Francis G, Rice G, Alsop J, Group PS. Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS. *Neurology* 2005;65:48–55.
4. Hegen H, Schleiser M, Gneiss C, et al. Persistency of neutralizing antibodies depends on titer and interferon-beta preparation. *Mult Scler Epub* 2011.
5. Polman CH, Bertolotto A, Deisenhammer F, et al. Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. *Lancet Neurol* 2010;9:740–750.

### CORRECTION

#### Focal atrophy on MRI and neuropathologic classification of dementia with Lewy bodies

In the article “Focal atrophy on MRI and neuropathologic classification of dementia with Lewy bodies” by K. Kantarci et al. (*Neurology*<sup>®</sup> 2012;79:553–560), there is an error in the author list. The seventh author’s name should read Melissa E. Murray. The authors regret the error.

Author disclosures are available upon request ([journal@neurology.org](mailto:journal@neurology.org)).

# Neurology<sup>®</sup>

## **Focal atrophy on MRI and neuropathologic classification of dementia with Lewy bodies**

*Neurology* 2012;79;1072

DOI 10.1212/WNL.0b013e31826d58ae

**This information is current as of September 3, 2012**

### **Updated Information & Services**

including high resolution figures, can be found at:  
<http://n.neurology.org/content/79/10/1072.full>

### **Permissions & Licensing**

Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:  
[http://www.neurology.org/about/about\\_the\\_journal#permissions](http://www.neurology.org/about/about_the_journal#permissions)

### **Reprints**

Information about ordering reprints can be found online:  
<http://n.neurology.org/subscribers/advertise>

*Neurology*® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright Copyright © 2012 by AAN Enterprises, Inc.. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.

